- Introduction to Clinical Research Training
- Medical Education
- United Kingdom Clinical Scholars Research Training
- Vanderbilt Hall
- Financial Aid
- Office of the Registrar
- Campus Planning and Facilities
- Ombuds Office
- Committee on Microbiological Safety
- Human Resources
- HMS Foundation Funds
- The Academy
- Office for Academic and Clinical Affairs
- Joint Committee on the Status of Women
- Global Health Research Core
- Global Clinical Scholars Research Training Program
- HMA Standing Committee on Animals
- Office of Research Compliance
- Global & Community Health
- Harvard Medical School Event Calendar
- Contact @HMS
- Office of Diversity RIA Program
- The Dean's Perspective
- Department of Pathology
- Harvard Mahoney Neuroscience Institute
- OHRA Home
- Office of Research Subject Protection
- Tools and Technology
- Alumni Association
- Cancer Biology & Therapeutics Program
- Celiac Program
- Department of Medicine
- HMS Community Values Initiative
- HMS Information Technology
- HMS TransMed Program
- Introduction to the Practice of American Medicine
- Office of Communications & External Relations
- Big Data In Healthcare
- Institutional Planning and Policy
- Master of Medical Sciences In Clinical Investigation
- Office of Global Education
- Portugal Clinical Scholars Research Training Program
- Safety Quality Informatics and Leadership
- Shenzhen-HMS Initiative in International Education
- South American Clinical Research Training
- test page
- Human Resources
- Jobs @ HMS
- Dental Medicine
- Harvard University
- Contact us
The most critical barrier for curing HIV-1 infection is the presence of the viral reservoir, the cells in which the virus can lie dormant for many years and avoid elimination by antiretroviral drugs. Very little has been uncovered about when and where the viral reservoir is established during acute HIV-1 infection, or the extent to which it is susceptible to early antiretroviral therapy (ART).
Now, a research team led by investigators at Beth Israel Deaconess Medical Center, in collaboration with the U.S. Military HIV Research Program, has demonstrated that the viral reservoir is established strikingly early after intrarectal simian immunodeficiency virus (SIV) infection of rhesus monkeys and before detectable viremia.
The findings appear online in the journal Nature.
“Our data show that in this animal model, the viral reservoir was seeded substantially earlier after infection than was previously recognized,” explained senior author Dan Barouch, HMS professor of medicine and director of the Center for Virology and Vaccine Research at Beth Israel Deaconess and steering committee member of the Ragon Institute of MGH, MIT and Harvard. “We found that the reservoir was established in tissues during the first few days of infection, before the virus was even detected in the blood.”
This discovery coincides with recent reports of the resurgence of HIV in the “Mississippi baby,” who was believed to have been cured by early administration of ART. “The unfortunate news of the virus rebounding in this child further emphasizes the need to understand the early and refractory viral reservoir that is established very quickly following HIV infection in humans,” added Barouch.
In this new study, the scientific team initiated suppressive ART in groups of monkeys on days 3, 7, 10 and 14 after intrarectal SIV infection. Animals treated on day 3 following infection showed no evidence of virus in the blood and did not generate any SIV-specific immune responses. Nevertheless, after six months of suppressive ART, all of the animals in the study exhibited viral resurgence when treatment was stopped.
While early initiation of ART did result in a delay in the time to viral rebound (the time it takes for virus replication to be observed in the blood following cessation of ART) as compared with later treatment, the inability to eradicate the viral reservoir with very early initiation of ART suggests that additional strategies will be needed to cure HIV infection.
“The strikingly early seeding of the viral reservoir within the first few days of infection is sobering and presents new challenges to HIV-1 eradication efforts,” explained James Whitney, HMS instructor in medicine at the Center for Virology and Vaccine Research at Beth Israel Deaconess, and lead author of the study. “Taken together, our data suggest that extremely early initiation of ART, extended ART duration and probably additional interventions that activate the viral reservoir will be required for HIV-1 eradication.”
This study was supported, in part, by the U.S. Military Research and Materiel Command and the U.S. Military HIV Research Program through its cooperative agreement with the Henry M. Jackson Foundation (W81XWH-07-2-0067; W81XWH-11-2-0174); the National Institutes of Health (AI060354; AI078526; AI084794; AI095985; AI096040; AI100645) and the Ragon Institute of MGH, MIT and Harvard.
Adapted from a Beth Israel Deaconess news release.